211 related articles for article (PubMed ID: 20652244)
1. Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles.
Pejawar-Gaddy S; Rajawat Y; Hilioti Z; Xue J; Gaddy DF; Finn OJ; Viscidi RP; Bossis I
Cancer Immunol Immunother; 2010 Nov; 59(11):1685-96. PubMed ID: 20652244
[TBL] [Abstract][Full Text] [Related]
2. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
Soares MM; Mehta V; Finn OJ
J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
[TBL] [Abstract][Full Text] [Related]
3. Generation of monoclonal antibodies of desired specificity using chimeric polyomavirus-derived virus-like particles.
Zvirbliene A; Samonskyte L; Gedvilaite A; Voronkova T; Ulrich R; Sasnauskas K
J Immunol Methods; 2006 Apr; 311(1-2):57-70. PubMed ID: 16516908
[TBL] [Abstract][Full Text] [Related]
4. Cellular and humoral immunogenicity of hamster polyomavirus-derived virus-like particles harboring a mucin 1 cytotoxic T-cell epitope.
Dorn DC; Lawatscheck R; Zvirbliene A; Aleksaite E; Pecher G; Sasnauskas K; Ozel M; Raftery M; Schönrich G; Ulrich RG; Gedvilaite A
Viral Immunol; 2008 Mar; 21(1):12-27. PubMed ID: 18355119
[TBL] [Abstract][Full Text] [Related]
5. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
[TBL] [Abstract][Full Text] [Related]
6. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.
Pietersz GA; Li W; Osinski C; Apostolopoulos V; McKenzie IF
Vaccine; 2000 Apr; 18(19):2059-71. PubMed ID: 10706970
[TBL] [Abstract][Full Text] [Related]
7. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.
Ohlschläger P; Osen W; Dell K; Faath S; Garcea RL; Jochmus I; Müller M; Pawlita M; Schäfer K; Sehr P; Staib C; Sutter G; Gissmann L
J Virol; 2003 Apr; 77(8):4635-45. PubMed ID: 12663770
[TBL] [Abstract][Full Text] [Related]
9. Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain.
Carmon L; El-Shami KM; Paz A; Pascolo S; Tzehoval E; Tirosh B; Koren R; Feldman M; Fridkin M; Lemonnier FA; Eisenbach L
Int J Cancer; 2000 Feb; 85(3):391-7. PubMed ID: 10652432
[TBL] [Abstract][Full Text] [Related]
10. Bioengineered Bovine Papillomavirus L1 Protein Virus-like Particle (VLP) Vaccines for Enhanced Induction of CD8 T Cell Responses through Cross-Priming.
Viscidi RP; Rowley T; Bossis I
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37372999
[TBL] [Abstract][Full Text] [Related]
11. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro.
Rudolf MP; Fausch SC; Da Silva DM; Kast WM
J Immunol; 2001 May; 166(10):5917-24. PubMed ID: 11342606
[TBL] [Abstract][Full Text] [Related]
12. Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity.
Schädlich L; Senger T; Gerlach B; Mücke N; Klein C; Bravo IG; Müller M; Gissmann L
J Virol; 2009 Aug; 83(15):7690-705. PubMed ID: 19457985
[TBL] [Abstract][Full Text] [Related]
13. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies.
Brossart P; Heinrich KS; Stuhler G; Behnke L; Reichardt VL; Stevanovic S; Muhm A; Rammensee HG; Kanz L; Brugger W
Blood; 1999 Jun; 93(12):4309-17. PubMed ID: 10361129
[TBL] [Abstract][Full Text] [Related]
14. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles.
Storni T; Lechner F; Erdmann I; Bächi T; Jegerlehner A; Dumrese T; Kündig TM; Ruedl C; Bachmann MF
J Immunol; 2002 Mar; 168(6):2880-6. PubMed ID: 11884458
[TBL] [Abstract][Full Text] [Related]
15. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.
Lakshminarayanan V; Thompson P; Wolfert MA; Buskas T; Bradley JM; Pathangey LB; Madsen CS; Cohen PA; Gendler SJ; Boons GJ
Proc Natl Acad Sci U S A; 2012 Jan; 109(1):261-6. PubMed ID: 22171012
[TBL] [Abstract][Full Text] [Related]
16. A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response.
Thönes N; Herreiner A; Schädlich L; Piuko K; Müller M
J Virol; 2008 Jun; 82(11):5472-85. PubMed ID: 18385253
[TBL] [Abstract][Full Text] [Related]
17. Chimeric HBcAg virus-like particles presenting a HPV 16 E7 epitope significantly suppressed tumor progression through preventive or therapeutic immunization in a TC-1-grafted mouse model.
Chu X; Li Y; Long Q; Xia Y; Yao Y; Sun W; Huang W; Yang X; Liu C; Ma Y
Int J Nanomedicine; 2016; 11():2417-29. PubMed ID: 27313455
[TBL] [Abstract][Full Text] [Related]
18. Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes.
Liu WJ; Liu XS; Zhao KN; Leggatt GR; Frazer IH
Virology; 2000 Aug; 273(2):374-82. PubMed ID: 10915608
[TBL] [Abstract][Full Text] [Related]
19. Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops.
Slupetzky K; Shafti-Keramat S; Lenz P; Brandt S; Grassauer A; Sara M; Kirnbauer R
J Gen Virol; 2001 Nov; 82(Pt 11):2799-2804. PubMed ID: 11602792
[TBL] [Abstract][Full Text] [Related]
20. Papillomavirus-like particles induce acute activation of dendritic cells.
Lenz P; Day PM; Pang YY; Frye SA; Jensen PN; Lowy DR; Schiller JT
J Immunol; 2001 May; 166(9):5346-55. PubMed ID: 11313370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
